Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Clinical Practice
  3. Oncology and Hematology

SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Comments
  • Overview

    P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: TAR-200 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer: Results from SunRISe-1 study.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Recommended
Details
Comments
  • Overview

    P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: TAR-200 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer: Results from SunRISe-1 study.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Schedule12 Oct 2024